
What is claimed:

1. A compound of Formula I:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or C_{1-8} alkyl;

R^4 is halogen, C_{1-8} alkyl, substituted C_{1-8} alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

R^6 is hydrogen, C_{1-8} alkyl, substituted C_{1-8} alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is $-(CH_2)_{1-8}-$, $-C(=O)-$, $-S(=O)_2NH-$, $-S(=O)_2-$,

$-C(=S)NH-$, $-S(=O)_2-CH_3$, $C(=O)-NH-$, $-S(=O)_2-NR^9R^{10}$, $-C(=O)C_{1-8}$ alkyl or

$-C(=O)CH(NH_2)CH_3$;

R^9 is hydrogen, C_{1-8} alkyl or substituted C_{1-8} alkyl;

R^{10} is hydrogen, C_{1-8} alkyl or substituted C_{1-8} alkyl;


R^5 is hydrogen, C_{1-8} alkyl, substituted C_{1-8} alkyl, aryl, substituted aryl, C_{1-8} alkenyl, substituted C_{1-8} alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;

R^7 is –OH or halogen; and

R^8 is hydrogen, halogen or C_{1-8} alkyl,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, Z is not present, R^7 is –OH, R^5, R^6 and R^8 are hydrogen.

2. A compound of Formula II:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or $–CH_3$;

R^4 is halogen, $–CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R^4 is a halogen, both R^2 and R^3 cannot be hydrogen;

R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R^6 is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is $–(CH_2)–$, $–C(=O)–$, $–S(=O)_2NH–$, $–S(=O)_2–$,

$-S(=O)_2-CH_3$, C(=O)–NH–, $-S(=O)_2NR^9R^{10}$, –C(=S)-NH– or $-C(=O)_2-CH_3$,

R^9 is hydrogen or CH_3;

R^{10} is hydrogen or CH_3;


R^5 is hydrogen or aminophenylalkyl;

R^7 is -OH or halogen; and

R^8 is hydrogen, halogen or $-CH_3$,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is halogen, Z is not present, R^7 is –OH, R^5, R^6 and R^8 are hydrogen.

3. A compound of Formula III:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or $-CH_3$;

R^4 is halogen, $-CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when R^4 is a halogen, both R^2 and R^3 cannot be hydrogen;


R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;


R^7 is -OH or halogen; and


R^8 is hydrogen, halogen or $-CH_3$,


provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, R^7 is –OH and R^6 and R^8 are hydrogen.


4. A compound selected from the following:








































































































































































or a pharmaceutically acceptable salt, or solvate thereof.


5. The compound of Claim 4 which is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


6. The compound of Claim 4 which is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


7. The compound of Claim 4 which is:



,

or a pharmaceutically acceptable salt, or solvate, thereof.


8. The compound of Claim 4 which is:



,

or a pharmaceutically acceptable salt, or solvate, thereof.

9. The compound of Claim 4 which is:



,

or a pharmaceutically acceptable salt, or solvate, thereof.

10. A pharmaceutical composition comprising the compound of Claim 1 and at least one pharmaceutically acceptable carrier.

11. A compound of Claim 1 for use in preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

12. Use of a compound of Claim 1 in the manufacture of a medicament for preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

13. A compound of Claim 2 for use in preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

14. Use of a compound of Claim 2 in the manufacture of a medicament for preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.


15. A compound of Claim 3 for use in preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

16. Use of a compound of Claim 3 for use in preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

17. A compound of Claim 4 for use in preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.

18. Use of a compound of Claim 4 in the manufacture of a medicament for preventing and/or treating Parkinson's disease in a patient at risk for developing or diagnosed with the same.


19. The compound of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


20. The use of Claim 18, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


21. The compound of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


22. The use of Claim 18, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


23. The compound of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


24. The use of Claim 18, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


25. The compound of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


26. The use of Claim 18, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


27. The compound of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

28. The use of Claim 18, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

29. The compound of Claim 11, wherein the prevention and/or treatment of Parkinson's disease involves at least one other therapeutic agent comprising levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.


30. The use of Claim 12, wherein the medicament comprises at least one other therapeutic agent including levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

31. A kit comprising:

- a container having an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof; and
- instructions for using the same to prevent and/or treat Parkinson's disease.

Claims:

1. A compound of Formula I:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or C_{1-8} alkyl;

R^4 is halogen, C_{3-8} alkyl, substituted C_{1-8} alkyl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring;

R^6 is hydrogen, C_{1-8} alkyl, substituted C_{1-8} alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is $-(CH_2)_{1-8}-$, $-C(=O)-$, $-S(=O)_2NH-$, $-S(=O)_2-$, $-C(=S)NH-$,

$-S(=O)_2-CH_2$, $C(=O)-NH-$, $-C(=O)C_{1-8}$, alkylene or $-C(=O)CH(NH_2)CH_2$;

R^9 is hydrogen, C_{1-8} alkyl or substituted C_{1-8} alkyl;

R^{10} is hydrogen, C_{1-8} alkyl or substituted C_{1-8} alkyl;

R^5 is hydrogen, C_{1-8} alkyl, substituted C_{1-8} alkyl, aryl, substituted aryl, C_{1-8} alkenyl, substituted


C_{1-8} alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;

R^7 is –OH or halogen; and

R^8 is hydrogen, halogen or C_{1-8} alkyl,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, Z is not present, R^7 is –OH, R^5, R^6 and R^8 are hydrogen.

2. A compound of Formula II:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or $–CH_3$;

R^4 is halogen, fluorophenyl, methylphenyl, cyclohexylmethyl;

R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R^6 is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is $–(CH_2)–$, $–C(=O)–$, $–S(=O)_2NH–$, $–S(=O)_2–$, $–S(=O)_2–CH_2$, $C(=O)–NH–$, $–C(=S)-NH–$ or $–C(=O)–CH_2$,

R^9 is hydrogen or CH_3;

R^{10} is hydrogen or CH_3;


R^5 is hydrogen or aminophenylalkyl;

R^7 is -OH or halogen; and

R^8 is hydrogen, halogen or $–CH_3$,

provided that R^2 and R^3 cannot both be hydrogen when R^4 is halogen, Z is not present, R^7 is –OH, R^5, R^6 and R^8 are hydrogen.

3. A compound of Formula III:



wherein:

R^1 is $C(R^2)(R^3)(R^4)$;

R^2 is hydrogen, -OH or halogen;

R^3 is hydrogen, -OH, halogen or $-CH_3$;

R^4 is halogen, $-CH_3$, phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl;


R^3 and R^4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;


R^7 is -OH or halogen; and


R^8 is hydrogen, halogen or $-CH_3$,


provided that R^2 and R^3 cannot both be hydrogen when R^4 is a halogen, R^7 is –OH and R^8 is hydrogen.


4. The compound of claim 1, wherein the compound is selected from the following:




































OH
F
HO
F
N
H



OH
F
HO
F
N
H



OH
F
HO
F
N



OH
F
HO
F
N



OH
F
HO
F
N



OH
F
HO
F
N
O































































or a pharmaceutically acceptable salt, or solvate thereof.


5. The compound of Claim 4, which is:



,


or a pharmaceutically acceptable salt, or solvate thereof.

6. The compound of Claim 4, which is:




or a pharmaceutically acceptable salt, or solvate thereof.

7. The compound of Claim 4, which is:



or a pharmaceutically acceptable salt, or solvate thereof.

8. The compound of Claim 4, which is:



or a pharmaceutically acceptable salt, or solvate thereof.

9. A pharmaceutical composition comprising the compound of Claim 1 and at least one pharmaceutically acceptable carrier.

10. A composition including the compound of Claim 1 for use in preventing and/or treating Parkinson's disease.

11. Use of a compound of Claim 1 in the manufacture of a medicament for preventing and/or treating Parkinson's disease.

12. A compound of Claim 2 for use in preventing and/or treating Parkinson's disease.

13. Use of a compound of Claim 2 in the manufacture of a medicament for preventing and/or treating Parkinson's disease.


14. A compound of Claim 3 for use in preventing and/or treating Parkinson's disease.

15. Use of a compound of Claim 3 for use in preventing and/or treating Parkinson's disease.

16. A compound of Claim 4 for use in preventing and/or treating Parkinson's disease.

17. Use of a compound of Claim 4 in the manufacture of a medicament for preventing and/or treating Parkinson's disease.


18. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


19. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


20. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


21. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


22. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


23. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


24. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


25. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


26. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

27. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

28. The composition of Claim 10, wherein the prevention and/or treatment of Parkinson's disease involves at least one other therapeutic agent comprising levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

29. The use of Claim 11, wherein the medicament comprises at least one other therapeutic agent selected from levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.


30. A kit comprising:


- a container having an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof; and
- instructions for using the same to prevent and/or treat Parkinson's disease.


31. The compound of Claim 1, wherein when R^3 and R^4 join with the carbon to which they are attached to form a cycloalkyl ring, the cycloalkyl ring is substituted with one or more halogen atoms.


32. The compound of Claim 31, wherein the cycloalkyl ring is substituted with one or more fluorine atoms.


33. A compound selected from the following:



























or a pharmaceutically acceptable salt, or solvate thereof.


34. A compound selected from the following:


















or a pharmaceutically acceptable salt, or solvate thereof.

35. A compound selected from:




,

or a pharmaceutically acceptable salt, or solvate thereof.

36. The pharmaceutical composition of Claim 9, wherein when R^3 and R^4 join with the carbon to which they are attached to form a cycloalkyl ring, the cycloalkyl ring is substituted with one or more halogen atoms.

37. The pharmaceutical composition of Claim 36, wherein the cycloalkyl ring is substituted with one or more fluorine atoms.

38. The pharmaceutical composition of Claim 9, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.